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Abstract
In clinical trials, a surrogate outcome variable (S) can be measured before
the outcome of interest (T) and may provide early information regarding the
treatment (Z) effect on T. Most previous methods for surrogate validation rely
on models for the conditional distribution of T given Z and S. However, S is
a post-randomization variable, and unobserved, simultaneous predictors of S
and T may exist. When such confounders exist, these methods do not have
a causal interpretation. Using the principal surrogacy framework introduced
by Frangakis and Rubin (2002), we propose a Bayesian estimation strategy
for surrogate validation when the joint distribution of potential surrogate and
outcome measures is multivariate normal. We model the joint conditional dis-
tribution of the potential outcomes of T, given the potential outcomes of S and
propose surrogacy validation measures from this model. By conditioning on
principal strata of S, the resulting estimates are causal. As the model is not
fully identifiable from the data, we propose some reasonable prior distributions
and assumptions that can be placed on weakly identified parameters to aid in
estimation. We explore the relationship between our surrogacy measures and
the traditional surrogacy measures proposed by Prentice (1989). The method
is applied to data from a macular degeneration study and data from an ovarian
cancer study, both previously analyzed by Buyse, et al. (2000).
Keywords: Bayesian estimation; Principal stratification; Surrogate end-
points.
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1 Introduction
A surrogate endpoint (S) is an intermediate outcome variable occurring in between
the treatment (Z) and the outcome of interest (T ). The surrogate is usually known
to be involved in the mechanism of the disease process and can be measured at an
earlier time than the desired outcome. Therefore, there is considerable interest in
the use of surrogate markers in clinical trials, as they offer the potential to run trials
more cheaply and quickly by extracting information regarding the treatment effect
on T through the earlier measured S. Examples of established surrogate markers
include blood pressure under anti-hypertensive drug treatment as a surrogate for
cardiovascular disease (Weir and Walley, 2006), and three year disease free survival
as a surrogate for five year overall survival in colorectal cancer (Sargent et al., 2007).
We examine two data examples in the application of our method. The first concerns
patients with age-related macular degeneration and considers the use of change in
visual acuity at 6 months after starting treatment as a surrogate marker for change
in visual acuity at 1 year. The second concerns ovarian cancer and assesses progression
free survival as a surrogate for overall survival.
Before a surrogate can be used in practice, it must be shown to be a valid surrogate
for the outcome of interest. In a landmark paper, Prentice (1989) proposed a formal
definition of surrogacy along with a validation strategy. Prentice’s criteria require
that S and T be correlated and the treatment effect on T be fully captured by
S. Other methods for surrogacy evaluation have since been proposed, including the
proportion of treatment effect explained by S (Freedman, Graubard, and Schatzkin,
1992), and individual-level and trial-level surrogacy association measures in meta-
analyses (Buyse, et al., 2000).
Some assessments of surrogacy rely on estimating treatment effects by adjusting
for a variable that is measured after randomization. However, there may be unmea-
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sured confounders in the pathway between the surrogate and final outcome resulting
in estimates that will not have a causal interpretation (Rosenbaum, 1984). Therefore,
Frangakis and Rubin (2002) (henceforth FR) introduced a definition of a surrogate
endpoint, called a “principal surrogate”, based on a principal stratification approach.
In this framework, each subject has two potential outcomes corresponding to each
treatment, denoted S(Z) and T (Z), for Z = 0, 1. The principal surrogacy approach
looks at the distribution of the potential outcomes of T conditional on principal strata
based on the joint distribution of S(0) and S(1). The principal strata are unaffected
by treatment, and are thus pre-randomization variables. Treatment effect estimates
that condition on these principal strata are therefore causal estimates when treat-
ments are randomly assigned.
The rationale for considering whether the principal stratification approach is ap-
propriate for assessing surrogacy has been discussed in the literature, with some
support provided in the discussion by VanderWeele (2011) and by Zigler and Belin
(2011). In this approach, the value of S as a surrogate for T is determined by the
extent to which the causal effect of treatment on S can reliably predict the causal
effect of treatment on T . The rationale for considering principal surrogacy or more
generally considering the joint distribution of S(0), S(1), T (0), T (1) is most easily ex-
plained in the case where S and T are binary. In this case, the joint distribution
of S(0), S(1), T (0), T (1) amounts to a partition of the population into cells with a
probability attached to each cell. These probabilities completely characterize the
population and from them an assessment of surrogacy can be made. For example,
one can consider the fraction of the population for which T (0) is not equal to T (1)
amongst those who have S(0) not equal to S(1). Then additionally, this fraction
might be contrasted with the fraction of the population for which T (0) is not equal
to T (1) amongst those who have S(0) equal to S(1). As we will describe below, other
4
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summary measures that can be obtained from the joint distribution might also be con-
sidered. When S and T are continuous, the joint distribution of S(0), S(1), T (0), T (1)
again completely characterizes the population, from which summary measures for as-
sessing surrogacy, such as the distribution of T (1) − T (0) given S(1) − S(0), can
be obtained. If one accepts that the joint distribution completely characterizes the
population, then the challenges are determining what useful summary measures to
extract from this distribution, and the estimation of this distribution.
We note that the principal stratification approach to assessing surrogacy uses
a causal framework, but the causal framework it uses differs from the framework
presented by Pearl (1995) and discussed in Joffe and Greene (2009). In the principal
stratification framework, there are only two causal effects, one on S and one on T and
we are interested in the association between these two. The other causal framework,
while it may also be interesting to consider, does require additional consideration of
the effect of S on T , requiring hypothetical manipulations of S. This alternative
causal framework is more mechanistic and allows notions of direct and indirect effects
of Z on T . We will not pursue it in this paper.
Existing literature on methods for surrogacy assessment using the principal strat-
ification approach has examined settings in which both S and T are binary (Li et al.
2010), or in which S is continuous with binary T (Gilbert and Hudgens, 2008; Zigler
and Belin, 2011). For a binary S and T , Li, et al. (2010) developed an estimation
method for the causal quantities associated with the cross classification of the poten-
tial outcomes using a log-linear model and Bayesian estimation procedure. Gilbert
and Hudgens (2008) (henceforth GH) used the framework of FR to develop an esti-
mand, termed the causal effect predictiveness (CEP) surface for evaluating surrogacy
when S is continuous or categorical and T is binary. Work in the PS framework
when both S and T are continuous has primarily been discussed in the application
5
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to partial compliance (Bartolucci and Grilli, 2011; Schwartz, et al., 2011). In this
context, the joint distribution of the potential outcomes of the intermediate variable,
in this case degree of compliance, is modeled either parametrically or semiparametri-
cally with principal causal effects (PCEs) measured by comparisons of the potential
outcomes of T conditional on S, where the conditional distributions for T (0) and
T (1) are modeled separately.
Here, we consider the entire joint distribution of (Si(0), Si(1), Ti(0), Ti(1)) and
propose estimands to evaluate principal surrogacy when both S and T are continuous
and the joint distribution of the potential outcomes is multivariate normal. Once
parameter estimates for this distribution are obtained, various causal quantities that
may aid in the assessment of S as a surrogate marker for T may be examined. Specific
quantities of interest include E[T (1)−T (0)|S(1), S(0)], P (T (1)−T (0) > 0|S(1), S(0)),
and the correlation between T (1) − T (0) and S(1) − S(0). The use of cor(T (1) −
T (0), S(1)−S(0)) has been discussed by Wang, et al. (2012), who specifically contrast
it with the observable correlation between S and T , given the treatment group.
Because some parameters of the joint distribution are not fully identifiable from
the data, we use a Bayesian estimation procedure with plausible prior distributions
and some reasonable constraints on model parameters to reduce the non-identifiability
problem of modeling counterfactual observations and to aid in estimation of the quan-
tities of interest. In order to facilitate the consideration of reasonable constraints we
found it convenient to decompose the covariance matrix, Σ of (Si(0), Si(1), Ti(0), Ti(1))
as Σ = QRQ (Barnard et al., 2000), and place constraints on the correlations R,
rather than on the covariance terms in Σ. We also explore the relationship between
some of the proposed surrogacy assessment quantities and those based on the well
known Prentice criteria. In Section 2, we describe the model and possible constraints
that could be made to facilitate estimation. In Section 3, we introduce surrogacy mea-
6
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sures based on the potential outcomes framework. Section 4 describes the Bayesian
estimation procedure that we use and Section 5 provides simulation results from this
procedure. In Section 6 we apply these methods to the macular degeneration data
and ovarian cancer data. Section 7 concludes with a discussion.
2 Potential Outcomes Model
For a randomized trial with treatment assignment Z (Z = 1 or 0), continuous sur-
rogate marker S and continuous true endpoint T , each subject i, i = 1, ..., n, has
two potential outcomes for each of Si and Ti, denoted by Si(Zi) and Ti(Zi). Only
one outcome, corresponding to the received treatment for subject i in each of the
pairs (Si(0), Si(1)) and (Ti(0), Ti(1)) can be observed. The joint distribution of
(Si(0), Si(1), Ti(0), Ti(1)) describes the causal associations between Z, S and T . In
the continuous setting where (Si(0), Si(1), Ti(0), Ti(1)) is multivariate normal with
mean µ and covariance matrix Σ, we have the following joint distribution:
Si(0)
Si(1)
Ti(0)
Ti(1)
 ∼ N


µS0
µS1
µT0
µT1
 ,

σ2S0 ρsσS0σS1 ρ00σS0σT0 ρ01σS0σT1
σ2S1 ρ10σS1σT0 ρ11σS1σT1
σ2T0 ρtσT1σT0
σ2T1


The mean µ and the variances corresponding to the diagonal elements of Σ, along
with the correlations between (Si(0), Ti(0)) and (Si(1), Ti(1)) corresponding to ρ00
and ρ11, are fully identifiable from the data. Because only one of the counterfactual
pairs of outcomes is observed for each subject, ρs, ρt, ρ01, and ρ10 are not identifiable.
However, the identifiable correlation parameters together with the requirement that
Σ be positive definite places boundary constraints on these non-identified parame-
ters, which, along with other plausible assumptions that we can make, aids in their
identifiability. These parameters are therefore considered to be partially identified as
opposed to completely unidentified.
7
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We make the standard assumptions of ignorable treatment assignments (Ru-
bin, 1978) and the stable unit treatment value assumption (SUTVA). Ignorable
treatment assignment implies that Z is independent of (S(0), S(1), T (0), T (1)) and
holds for blinded, randomized trials. SUTVA implies that the potential outcomes
(Si(0), Si(1), Ti(0), Ti(1)) are independent of the treatment assignments of other sub-
jects. This allows us to write the potential outcomes for subject i as a function of Zi
rather than of the entire vector of subject treatment assignments.
Other context specific constraints can be added, such as all ρ’s ≥ 0, a plausible
assumption for most variables S that would be under consideration as a potential
surrogate for T , and especially when the identifiable Pearson correlation coefficients,
ρˆ00 and ρˆ11, are positive. Other plausible assumptions are ρ01 < min(ρ00, ρ11, ρs, ρt),
and ρ10 < min(ρ00, ρ11, ρs, ρt), indicating a belief that the correlation between the
surrogate response and final outcome response in opposite treatment arms is less
than the correlation between the surrogate response and final outcome response within
the same treatment arm, or the correlation between the surrogate responses or final
treatment responses across treatment arms.
3 Assessing Surrogacy Using Potential Outcomes
Framework
3.1 Definitions of Surrogacy
Because S is a post-randomization variable, unobserved simultaneous predictors of
both S and T may exist. In this case, methods of surrogacy assessment that re-
quire conditioning on S do not result in causal estimates (Rosenbaum, 1984). When
baseline covariates account for all common causes of S and T , surrogacy measures
that condition on S will be causal. However, the assumption of no unmeasured con-
founders of S and T is untestable, potentially leading to noncausal estimates (Gilbert,
8
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et al., 2009). Therefore, FR proposed a definition of principal surrogacy (PS), which
uses a principal stratification approach to assess the validity of a surrogate marker.
This framework focuses on the distribution of p(T (0), T (1)|S(0), S(1)). Since S(1)
and S(0) are unaffected by treatment assignment, they can be treated as baseline
covariates. Quantities estimated from this distribution will therefore always have a
causal interpretation. FR proposed two measures of surrogacy, the “associative ef-
fect” and the “dissociative effect”. A measure of the associative effect is given by
E(Ti(1) − Ti(0)|Si(1) = Si(0)) and a measure of the dissociative effect is given by
E(Ti(1)− Ti(0)|Si(1) 6= Si(0)).
For the multivariate normal distribution, the distribution of (T (1)− T (0)|S(1)−
S(0) = s) is normal with mean
(µT1 − µT0) +
(
ρ11σS1σT1−ρ10σS1σT0−ρ01σS0σT1+ρ00σS0σT0
σ2S0
+σ2S1
−2ρsσS0σS1
)
(s− (µS1 − µS0))
and variance
σ2T0 + σ
2
T1
− 2ρtσT0σT1 − (
ρ11σS1σT1−ρ10σS1σT0−ρ01σS0σT1+ρ00σS0σT0)
2
σ2S0
+σ2S1
−2ρsσS0σS1
.
The mean can be written as E[Ti(1)− Ti(0)|Si(1)− Si(0) = s] = γ0 + γ1s, where
γ0 = (µT1 − µT0 )−
(
ρ11σS1σT1 − ρ10σS1σT0 − ρ01σS0σT1 + ρ00σS0σT0
σ2S0 + σ
2
S1
− 2ρsσS0σS1
)
(µS1 − µS0 )
γ1 =
(
ρ11σS1σT1 − ρ10σS1σT0 − ρ01σS0σT1 + ρ00σS0σT0
σ2S0 + σ
2
S1
− 2ρsσS0σS1
)
The value of γ0 is then a measure of the “dissociative effect”. Values of γ0 near zero
indicate that the causal effect of treatment on the final outcome is near zero when the
causal effect of treatment on the surrogate is near zero, a characteristic that a good
principal surrogate should possess. When γ0 is near (µT1−µT0), there can be a causal
effect of the treatment on the final outcome even if there is no causal effect of the
treatment on the surrogate, implying that the treatment affects the outcome through
9
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pathways that do not involve the surrogate. We note, however, that a dissociative
effect of zero does not exclude the possibility of these pathways. The value of γ0 +γ1s
is a measure of the “associative effect”, providing information on how the causal
treatment effect on the outcome changes as the causal effect of the treatment on
the surrogate changes. A good principal surrogate should result in a large associative
effect, indicating that as the treatment effect on the surrogate increases, the treatment
effect on the final outcome increases as well. This does not imply an indirect effect
of treatment on the outcome or an effect of S on T , but rather the extent to which
the effect of Z on S is associated with an effect of Z on T (VanderWeele, 2011).
GH suggest a refined definition of a principal surrogate endpoint. In their setting
with binary T they define two properties, “average causal necessity” (ACN) and
“average causal sufficiency” (ACS). ACN is satisfied if risk(1)(s1, s0) = risk(0)(s1, s0)
for all s1 = s0, where risk(z)(s1, s0) = p(T (Z) = 1|S(1) = s1, S(0) = s0). ACS is
satisfied if there exists some constant C ≥ 0 such that risk(1)(s1, s0) 6= risk(0)(s1, s0)
for all |s1 − s0| > C. GH suggest that a valid surrogate marker should satisfy both
ACS and ACN. In our setting of continuous T , we can consider the joint conditional
distribution of (T (0), T (1)). Specific summaries of this joint distribution which are
of major interest include E[T (1) − T (0)|S(1) − S(0) = s] for s = 0 and |s| > C
for some constant C ≥ 0, P (T (1) > T (0)|S(1), S(0)) and the correlation between
T (1)−T (0) and S(1)−S(0). Also of interest is the “causal effect predictiveness (CEP )
surface” proposed by GH which considers the entire curve of E[T (1)−T (0)|S(1), S(0)]
and provides a measure of the treatment effect on T within subgroups defined by
the treatment effect on the surrogate. In terms of expectations, ACN is satisfied if
E[T (1)−T (0)|S(1)−S(0) = 0] = 0 and ACS is satisfied if E[T (1)−T (0)|S(1)−S(0) =
s] 6= 0 for all |s| > C. In the above setting, this corresponds to γ0 = 0 and γ1 6= 0.
In terms of the entire conditional distribution of T (1) − T (0) given (S(1) − S(0)),
10
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ACN is satisfied if P (T (1) − T (0) > 0|S(1) − S(0) = 0) = 0.5 and ACS is satisfied
if P (T (1) − T (0) > 0|S(1) − S(0) > 0) increases as S(1) − S(0) increases. For
multivariate normal data this conditional probability is:
Φ10(s) = P (T (1)− T (0) > 0|S(1)− S(0) = s) = Φ
 γ0 + γ1s√
σ2T0 + σ
2
T1
− 2ρtσT0σT1 − γ21(σ2S0 + σ2S1 − 2ρsσS0σS1 )

In the multivariate normal setting, these two metrics of ACN and ACS are closely
related. If γ0 = 0, then Φ10 = 0.5 when S(1)−S(0) = 0 and if γ1 > 0, then Φ10 > 0.5
when S(1) − S(0) > 0. So the conclusion drawn regarding the validity of S as a
surrogate will be the same under these two measures.
Another potentially useful measure to assess surrogacy is the correlation between
T (1) − T (0) and S(1) − S(0), which we denote by ρST . It can be shown that ρST is
given by
ρST =
ρ11σS1σT1−ρ10σS1σT0−ρ01σS0σT1+ρ00σS0σT0√
σ2S0
+σ2S1
−2ρsσS0σS1
√
σ2T0
+σ2T1
−2ρtσT0σT1
A final way that we consider summarizing the conditional distribution of T (1)−
T (0) given S(1) − S(0) = s, and hence assessing surrogacy, is through the CEP
graph, which is a plot of E[T (1)− T (0)|S(1)− S(0) = s] versus s, which is simply a
plot of γ0 + γ1s versus s.
3.2 Relationship Between Principal Surrogacy Measures and
Prentice Surrogacy Criteria
The ACN and ACS measures corresponding to conditional expectation can be linked
to the original surrogacy definition proposed by Prentice (1989). Prentice’s criteria
11
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for a valid surrogate require that
f(T |Z) 6= f(T )
f(S|Z) 6= f(S)
f(T |S) 6= f(T )
f(T |S,Z) = f(T |S)
In the multivariate normal setting with
E[Ti|Zi] = θ0 + θ1Zi
E[Si|Zi] = α0 + α1Zi
E[Ti|Si] = µ0 + µ1Si
E[T |S,Z] = β0 + β1Z + β2S + β3SZ
the Prentice criteria are satisfied when θ1 6= 0, α1 6= 0, µ1 6= 0, β1 = 0, β2 6= 0, and
β3 = 0. Relating these to the parameters in the potential outcomes model we have
θ1 = µT1 − µT0
α1 = µS1 − µS0
µ1 =
1
2
(
ρ00σT0
σS0
+
ρ11σT1
σS1
)
β1 = (µT1 − µT0)−
(
ρ11σT1
σS1
µS1 −
ρ00σT0
σS0
µS0
)
β2 =
ρ00σT0
σS0
β3 =
ρ11σT1
σS1
− ρ00σT0
σS0
It can be shown that when
ρ11σT1
σS1
=
ρ00σT0
σS0
(1)
12
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and
ρ00ρs =
1
2
(
ρ10 + ρ01
σS0σT1
σS1σT0
)
(2)
we have γ1 = β2 = µ1, γ0 = β1 and β3 = 0. Therefore, under these conditions, the
Prentice criteria and the principal surrogacy criteria requiring that both ACN and
ACS be met (or γ0 = 0 and γ1 6= 0) will reach the same conclusions regarding the
validity of S as a surrogate. When the above conditions are not met, conflicting
conclusions may be drawn by the Prentice criteria and principal surrogacy criteria.
As we regard principal surrogacy to be the main objective in surrogacy assessment,
approaching the question of surrogacy using the Prentice criteria in this case may
lead to erroneous conclusions.
In any real setting we would not expect the conditions in equations 1 and 2 to be
exactly satisfied. However, in many settings we can see that the Prentice criteria and
principal surrogacy criteria will reach similar conclusions. Often σS0 ≈ σS1 , σT0 ≈ σT1
and we might expect ρ00 to be similar to ρ11, thus equation 1 is approximately satisfied.
Similarly we may expect ρ01 and ρ10 to be similar and hence their average to be less
than both ρ00 and ρs; thus departures from equality in equation 2 may not be large.
3.3 Parameter Identifiability and Restrictions
Given the identified parameters, the positive definite restriction on R, and plausi-
ble assumptions about correlation values, we can gain some insight into the possible
ranges, or “identification regions” (Gustafson, 2010) for the partially identified pa-
rameters and examine scenarios within this space which lead to different surrogacy
conclusions. Under the restriction that all ρ’s are non-negative, and the simplifying
assumptions that ρ01 = ρ10, ρ11 = ρ00, and σS0 = σS1 = σT0 = σT1 , the top half of
Figure 1 displays the possible ranges for ρ01 = ρ10 across different values of ρs and
ρt for a given ρ11 = ρ00, where ρ11 and ρ00 are the identifiable Pearson correlation
13
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coefficients between Si(1) and Ti(1), and Si(0) and Ti(0), respectively. The length of
the identification region for ρ01 and ρ10 is smallest when ρ11 and ρ00 are large. For all
values of ρ11 and ρ00, the length of the identification region for ρ01 and ρ10 decreases
as ρs and ρt increase. The bottom half of Figure 1 provides ranges for these param-
eters under the additional restriction that ρ01 < min(ρ00, ρ11, ρs, ρt). This restriction
greatly reduces the range of possible values for the partially identified parameters, and
has implicit effects on the possible ranges for γ0 and γ1. Under these restrictions, γ1
must be greater than 0, implying that ACS always holds. In this scenario where ACS
always holds, poor principal surrogates can be characterized by large values of γ0,
implying that the treatment can effect the outcome without effecting the surrogate.
Alternatively, a poor surrogate would have a small value of γ1, implying that there
is still a positive, but weak association between causal effects on the surrogate and
causal effects on the outcome. These restrictions seems reasonable, as S is typically
known to somehow be associated with or a relevant aspect of the disease process, so
even if it is not a valid principal surrogate from an ACN and ACS perspective, we
expect there to be at least a small association of treatment effects on S with treat-
ment effects on T . The solid points in each figure are parameter values under which
the Prentice criteria and PS criteria are in agreement. In this restricted space the
deviation between the Prentice criteria and the PS criteria are less than in the unre-
stricted space, however we see that scenarios can arise in which the Prentice criteria
lead to incorrect conclusions regarding the validity of a principal surrogate.
4 Estimation Procedure
A Bayesian approach is used to estimate parameters. Unobserved potential outcomes
are treated as missing data and imputed from the appropriate posterior distribution at
each iteration of the Markov chain. The covariance matrix Σ is decomposed as QRQ,
14
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(f) ρ00 = ρ11 = 0.3
Figure 1: Identification Regions of Unidentified Parameters
Plots (a), (b), and (c): under restriction ρ’s ≥ 0
Plots (d), (e), and (f): under restriction ρ’s ≥ 0, ρ01 < min(ρ00, ρ11, ρs, ρt)
Solid points: PS criteria and Prentice criteria in agreement
where Q is the diagonal matrix of standard deviations and R is the correlation matrix.
Assuming a priori independence, this allows us to factor the prior distribution p(µ,Σ)
as p(µ)p(R)p(Q) and to place non-informative priors on the fully identified parameters
µ, Q, ρ00, and ρ11. Specifically, the prior for µ is N4(0,Σ0), where Σ0 = diag(10
6), and
the prior for each diagonal element of Q is p(σj) ∝ 1, for j = (S(0), S(1), T (0), T (1)).
We place marginal priors on each of the correlation parameters in R and explore
the use of four different prior assumptions. For each of these there is the additional
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assumption that R must be positive definite. The four priors are
(a) Jointly uniform prior such that for each of the six correlations p(ρ) ∼ Unif(−1, 1)
(b) Jointly uniform prior such that for each of the six correlations p(ρ) ∼ Unif(0, 1)
(c) All ρ′s ≥ 0, ρ01 < min(ρ00, ρ11, ρs, ρt), and ρ10 < min(ρ00, ρ11, ρs, ρt)
(d) Beta priors such that:
• p(ρ11) ∼ Unif(0, 1)
• p(ρ00) ∼ Unif(0, 1)
• p(ρ10) and p(ρ01) ∼ Beta(3α0, 3− 3α0) such that P (ρ01, ρ10 ≤ min(ρˆ00, ρˆ11)) = 0.80
• p(ρs) and p(ρt) ∼ Beta(3α1, 3− 3α1) such that P (ρs, ρt ≥ max(ρˆ10, ρˆ01)) = 0.80
where ρˆ00 and ρˆ11 are the Pearson correlation coefficients estimated from the observed
data. Prior assumption (a) is a non-informative prior on all of the correlations. Under
scenario (b), all correlations are constrained to be positive, a plausible assumption
especially when ρˆ00 and ρˆ11 are positive. In scenario (c), in addition to the positiv-
ity assumption, we restrict ρ01 and ρ10 to be smaller than the other four correlation
parameters. This seems reasonable as ρ01 and ρ10 are measures of the correlation be-
tween the surrogate response and final outcome response in opposite treatment arms,
which is unlikely to be larger than the correlation between the surrogate response and
final outcome response within the same treatment arm, or the correlation between
the surrogate responses or final treatment responses across treatment arms. Finally,
prior assumption (d) places similar restrictions on the correlations as assumption (c),
but is a little bit more flexible as ρ01 and ρ10 are only assumed to be smaller than
the other correlations with a probability of 0.8. Appendix A provides density plots
of the Beta priors when ρˆ00 and ρˆ11 are equal to 0.8, 0.5, and 0.3.
Posterior estimates of the unobserved potential outcomes, parameter values, and
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the causal quantities of interest, γ0, γ1, Φ10(0), ρST , and the CEP curve at the points
(µS1 − µS0) ± 2SD(S(1) − S(0)), where SD(S(1) − S(0)) is the standard deviation
of (S(1) − S(0)), are obtained using the Gibbs sampler. Each component of Q and
R are drawn one at a time. When drawing each element of R, the range of possible
values must first be determined in order to satisfy the positive definite requirement,
given that the other correlations are held fixed. The range of values corresponding
to a positive definite matrix are those in the interval determined by the roots of the
quadratic equation that result from solving |R| = 0. The specific equations solved to
obtain parameter ranges are provided in Appendix B.
As the posterior distributions for the components of Q and R can not be easily
sampled from, draws are made using the griddy Gibbs sampler (Ritter and Tanner,
1992). Details of the Gibbs sampler are provided in Appendix C.
5 Simulations
We conduct simulations to evaluate the performance of the above methods of surro-
gacy assessment. We consider the scenarios where under the true parameter values of
the simulated data, surrogate validity is the same (S is valid, or S is invalid) under
both the Prentice criteria and PS criteria. We also consider the two cases where,
under the true parameter values of the simulated data, the surrogacy conclusions
drawn using the Prentice criteria would reach a different conclusion from that drawn
using the PS criteria (S valid under Prentice but not under PS, and S valid under PS
but not under Prentice). In this paper we interpret the results from the perspective
that principal surrogacy is the correct approach. We investigate whether the wrong
conclusions would be reached if the Prentice criteria were used instead, and whether
it is easier to validate a principal surrogate depending on whether or not the Prentice
criteria are also satisfied. Table 1 provides details of the four simulations considered.
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Table 1: Simulation Models
(1) S is a valid (2) S is not a valid (3) S is not a valid (4) S is a valid
principal surrogate; principal surrogate; principal surrogate; principal surrogate;
does not satisfy satisfies does not satisfy satisfies
Prentice criteria Prentice criteria Prentice criteria Prentice criteria
ρs 0.5 0.5 0.2 0.4
ρ00 0.7 0.5 0.2 0.8
ρ01 0.15 0.45 0.04 0.32
ρ10 0.15 0.45 0.04 0.32
ρ11 0.7 0.5 0.2 0.8
ρt 0.18 0.5 0.3 0.4
σ∗ 1 1 1 1
γ0 0 0.8 1.1 0
γ1 1.1 0.1 0.2 0.8
ρST 0.86 0.1 0.21 0.8
β1 0.8 0 1.1 0
β2 0.7 0.5 0.2 0.8
β3 0 0 0 0
ρ00ρs 0.35 0.25 0.04 0.32
1
2
(
ρ10 + ρ01
σS0σT1
σS1σT0
)
0.15 0.45 0.04 0.32
*σ = σS0 = σS1 = σT0 = σT1
We first use these four models to explore the sensitivity of the estimation to the
plausible prior restrictions on R that we might make. We simulate 200 data sets
under each of the above mentioned priors for the four different surrogacy scenar-
ios. Table 2 provides the posterior means and standard deviations of the Bayesian
estimates and means of the posterior standard deviations ( ¯PSD). The identified pa-
rameters are not sensitive to changes in the prior specifications while, as expected,
the unidentified parameters are quite sensitive to prior assumptions. In all four sce-
narios, the standard deviation of the Bayesian estimates is smaller than ¯PSD for
the unidentified parameters. Table 3 provides the means and standard deviations
of the Bayesian estimates and ¯PSD for the quantities of interest from the Prentice
model, and the causal quantities of interest, γ0, γ1, ρST , Φ10(0) and the CEP curve
at (µS1 −µS0)± 2SD(S(1)−S(0)). There is very little bias in estimating β1, β2, and
β3, while there is some bias in estimating γ0, γ1, ρST , Φ10(0) and the CEP points, as
these are functions of unidentified parameters. The estimation performed using Beta
priors appears to provide the best estimation for the unidentified parameters across
18
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these four models. While this prior does not always perform best in terms of bias, it
has on average better coverage of the parameters across the different scenarios than
the other models, and therefore better power to determine the validity of S.
We investigate how well the estimation procedure is able to identify the validity
of S as a surrogate marker under Beta priors. Table 4 provides an estimate of the
proportion of times that S would be considered a good principal surrogate based on
the proposed measures. For γ0 and γ1 this means that 0 is in the 95% credible interval
for γ0, and outside of the 95% credible interval for γ1. For Φ10(0) this means that 0.5
is in the 95% credible interval. For ρST , we look at the proportion of times that its
credible interval is outside of 0, and for the CEP curve we look at the proportion of
times that the 95% credible intervals at the points (µS1−µS0)+2SD(S(1)−S(0)) and
(µS1 − µS0)− 2SD(S(1)− S(0)) do not overlap (denoted by CEPU−2SD < CEPL+2SD).
Table 4 also provides an estimate of the proportion of times that S would be a valid
surrogate based on the Prentice criteria (0 in the 95% confidence interval for βˆ1, and
βˆ3 and 0 outside of the 95% confidence interval for βˆ2 in a regression on the observed
data) for the four simulation scenarios considered. The entire CEP curve, shown in
Figure 2, is also used to visually assess principal surrogacy and the expected treatment
effect on T at relevant values of S(1)−S(0). We explored additional models under each
of the four surrogacy scenarios to gain a better understanding of how our estimation
procedure performs across the parameter space. The results presented appear to be
characteristic of most models that would fit into each of the four scenarios.
Our estimation procedure for γ0 and γ1 reaches the correct conclusion regarding
surrogate validity when principal surrogacy is unmet, regardless of whether or not
the Prentice criteria are met under the true parameters. We correctly identify S as a
poor principal surrogate 99% of the time in the scenario in which S is invalid under
the Prentice criteria, and 85% of the time when S is valid under the Prentice criteria.
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In comparison, the Prentice criteria incorrectly determine S to be a valid surrogate
26% and 92% of the time, respectively, in these two scenarios. When S is in truth a
good principal surrogate, our procedure most reliably determines surrogate validity
when the Prentice criteria would also conclude that S is a good surrogate. In this
scenario, we correctly identify S as a valid principal surrogate 94% of the time, while
the Prentice criteria conclude S to be a good surrogate 95% of the time. When S is a
good principal surrogate but the Prentice criteria show S to be invalid, our estimation
procedure and the Prentice approach have a similar ability to detect surrogacy, with
neither approach providing reliable surrogacy conclusions. In the scenario considered,
our estimation procedure correctly identified S as a good surrogate 37% of the time,
while the Prentice approach correctly identified S as a good surrogate 52% of the
time.
We note that by basing surrogacy assessment on the criteria that γ0 = 0 and
γ1 6= 0, we do not avoid the problem that is inherent in the Prentice criteria of proving
a null hypothesis, namely that certain parameters assume the value of 0. Therefore,
in addition to these quantities, we can also examine the other proposed estimands to
aid in validating S as a surrogate. The tests of ρST = 0 and CEP
U
−2SD < CEP
L
+2SD
have similar power to correctly determine surrogacy. When S is a poor principal
surrogate, the two quantities reject surrogacy 83% and 85% of the time, respectively,
when the Prentice criteria are in truth satisfied, and 99% of the time when they are
not. In the two scenarios where S is a good principal surrogate, these two quantities
improve upon the γ0, γ1 criteria, correctly determining surrogacy a majority of the
time, with greater power to detect surrogacy in the scenario where the Prentice criteria
are also met. Principal surrogacy is correctly identified 57% and 55% of the time,
respectively, when the Prentice criteria are not met and 94% and 93% of the time,
respectively, when the Prentice criteria are also met. In contrast, while the criterion
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of Φ10(0) = 0.5 being included in the 95% credible interval does reasonably well at
determining surrogacy when the Prentice criteria and PS criteria are in agreement,
it is unable to reliably distinguish good principal surrogates from poor ones with the
two criteria disagree.
Figure 2: Simulation results: CEP curves
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6 Application
6.1 Early Change in Visual Acuity as a Surrogate for Later
Change in Visual Acuity in a Trial of Age-related Mac-
ular Degeneration
We apply our estimation method to a clinical trial for 183 patients with age-related
macular degeneration. This data set was considered in a previous paper by Buyse,
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et al. (2000) where a meta-analysis surrogate validation strategy was used. These
data come from a multicenter trial comprised of 36 different centers. The number of
patients per center ranges from 2 to 18. In this example, we have a binary treatment
indicator (Zi) equal to 0 for placebo and 1 for the treatment, interferon-α. The
surrogate marker (Si) is change in visual acuity at 6 months after starting treatment
and the final endpoint (Ti) is change in visual acuity at 1 year. We first check
the Prentice criteria, subtracting off the Best Linear Unbiased Predictor (BLUP)
estimates from Si and Ti to account for random center effects. We have:
θˆ1 = −3.34(SE = 2.13, P = 0.12)
αˆ1 = −2.03(SE = 1.90, P = 0.29)
µˆ = 0.65(SE = 0.07, P < 0.0001)
βˆ1 = −2.67(SE = 1.94, P = 0.17), βˆ2 = 0.69(SE = 0.09, P < 0.0001),
βˆ3 = −0.11(SE = 0.14, P = 0.44)
As θ1 and α1 are not statistically significant, the Prentice criteria are not met. Using
our Bayesian estimation procedure with Beta priors for the correlation parameters,
we get the following posterior estimates for the principal surrogacy parameters of
interest:
γ0 = −1.62(−5.49, 2.16)
γ1 = 0.60(−0.24, 1.43)
As γ1 contains 0 within its 95% credible interval, we conclude that change in visual
acuity at 6 months is not a valid principal surrogate for change in visual acuity at 12
months. The average Pearson correlation, ¯ρST of Ti(1)− Ti(0) and Si(1)− Si(0) was
0.48 (-0.16, 0.92), also indicative of a poor principal surrogate. This is in agreement
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with the conclusion reached by Buyse, et al. (2000) in their analysis. Figure 3(a)
shows a plot of the (CEP ) curve, where CEP = E[T (1) − T (0)|S(1) − S(0) = s]
with a 95% credible interval for each value of s. The middle dashed line indicates
the posterior mean of µS1 − µS0 , and the outer two dashed lines show the posterior
means of µS1 − µS0 ± 2SDS(1)−S(0), where SDS(1)−S(0) is the standard deviation of
S(1) − S(0), given by
√
σ2S0 + σ
2
S1
− 2ρsσS0σS1 . The plot shows that 0 is contained
within the credible interval at almost all values of s, indicating that there could be
large effects of treatment on the surrogate with no expected effect of treatment on
the outcome. Similarly, when there is no treatment effect on S, there could still be a
treatment effect on T .
6.2 Progression Free Survival Time as a Surrogate for Over-
all Survival Time in an Ovarian Cancer Trial
Our second data application is to data from a randomized trial in advanced ovarian
cancer. This trial along with 3 others were analyzed by Buyse, et al. (2000) using a
meta-analytic validation method, with the center in which patients were treated in
each trial as the unit of analysis. In the trial we examine, a total of 274 women were
treated for ovarian cancer in two treatment arms. Of these patients, 201 experienced
a cancer progression prior to death, and 43 died without recurrence. The remaining
30 patients were censored for death and were not considered in the analysis. Again,
we have a binary treatment with 126 subjects in the control arm and 118 in the
treatment arm. The surrogate marker is progression free survival (PFS) time, in
months and the final endpoint is overall survival (OS) time, in months. As both of
these outcomes were right skewed, a log-transformation was taken to normalize the
data. Estimates of parameters used to assess the validity of the Prentice criteria are
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as follows:
θˆ1 = 0.07(SE = 0.13, P = 0.58)
αˆ1 = 0.17(SE = 0.14, P = 0.23)
µˆ = 0.90(SE = 0.02, P < 0.0001)
βˆ1 = −0.26(SE = 0.17, P = 0.13), βˆ2 = 0.88(SE = 0.03, P < 0.0001),
βˆ3 = 0.05(SE = 0.04, P = 0.27)
As in the macular degeneration data, θ1 and α1 are not statistically significant, and the
Prentice criteria are therefore unmet. We obtain the following posterior estimates for
the causal quantities of interest using our method with Beta priors on the unidentified
parameters:
γ0 = −0.08(−0.17, 0.007)
γ1 = 0.94(0.83, 1.09)
The 95% credible interval for γ0 (barely) contains 0 while the 95% credible interval
for γ1 does not and ¯ρST was 0.93 (0.87, 0.98). We therefore conclude that progression
free survival time is a marginally valid principal surrogate for overall survival. This
agrees with the findings of Buyse, et al. (2000), who concluded that progression
free survival could be used as a surrogate for overall survival in advanced ovarian
cancer. Figure 3(b) provides a plot of the CEP curve and 95% credible interval
at each S(1) − S(0) = s, with both S and T on the log scale. The middle and two
outer dashed lines indicate the posterior mean of µS1−µS0 , and the posterior means of
µS1−µS0±2SDS(1)−S(0), respectively. The plot shows that when there is no treatment
effect on S, there is little or no expected treatment effect on T , and as the treatment
effect on S increases, the treatment effect on T is also expected to increase.
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Figure 3: CEP Curves for Data Examples
7 Discussion
In this article, we develop a method for the assessment of surrogate markers within the
principal surrogate framework. We assume a multivariate normal distribution for the
potential surrogate outcomes and potential final outcomes and derive quantities that
may be useful in determining the validity of a surrogate marker. Through our model
setup, context specific assumptions can be incorporated into the prior distributions
of unidentified parameters to aid in estimation. The estimation procedure can be
extended to scenarios where T is partially missing, or to the multiple trial setting.
We compare some of the proposed quantities for surrogate validation to the orig-
inal validation criteria put forth by Prentice and show that, in many settings, we
might expect the Prentice and principal surrogacy criteria to be in agreement. Based
on our simulation study, it appears that when principal surrogacy is present, it is
most accurately determined in cases where the Prentice criteria would also correctly
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identify surrogacy. When principal surrogacy is not present, it can be determined
both when the Prentice criteria are able to correctly identify S as invalid and when
the Prentice criteria incorrectly deem S to be valid. We note that even with the use
of informative priors to aid in the estimation of the partially identified parameters,
the coverage rates in many cases are not ideal.
Each of the proposed quantities have merits and drawbacks in terms of their ability
to characterize surrogacy. The proposed γ0 and γ1 quantities are easily interpretable,
but proving that γ0 is equal to 0, a necessary condition for a valid surrogate, is diffi-
cult to do in practice. The correlation measure, ρST , captures the causal correlation
between the treatment effect on the surrogate and the treatment effect on the out-
come, but fails to capture the concept of ACN. The CEP graph provides a way to
estimate expected treatment effects on T when treatment effects on S are at relevant
clinical values, but does not offer a single summary of the value of S as a surrogate.
Finally, the Φ10 quantity provides information about the entire conditional distribu-
tion, as opposed to just the expectation, but is more difficult to estimate and seems
to have poor properties. While no single parameter estimate can completely assess
principal surrogacy, a variety of measures that consider the distribution of the causal
effect of treatment on the outcome conditional on the causal effect of treatment on
the surrogate can be used in combination to provide evidence as to whether or not S
is a valid surrogate for T .
Due to the nonidentifiability of some parameters in our model, certain assumptions
on the relationships between nonidentifiable associations were made and informative
priors were used for unidentified parameters to aid in estimation. The use of other
priors or other context specific assumptions about parameters could be made. Zigler
and Belin (2011) also explore the effects of various model assumptions in a principal
surrogacy estimation procedure. They use a Bayesian estimation approach for the
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CEP surface when S is continuous and T is binary. In their procedure, priors are
placed on the regression coefficients of the CEP surface, and an independence as-
sumption is made for T (1) and T (0) conditional on the surrogate and other baseline
covariates.
Previous work on principal surrogates has focused on binary endpoints (Li et al.,
2010) or a categorical or continuous surrogate outcome with a binary or continuous
final endpoint with the conditional distributions of pairs of potential outcomes esti-
mated separately (Gilbert and Hudgens, 2008). Qin et al. (2008) used a principal
stratification approach in the assessment of a continuous surrogate with a time to
event outcome. Extensions to other common data types, such as the setting where
both the surrogate and final outcome are time to event endpoints, may be possible
through the use of multivariate copula models.
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Table 2: Simulation Results Under Different Prior Specifications
Identified Parameters
S Valid PS, S Invalid PS, S Invalid PS S Valid PS
S Invalid Prentice S Valid Prentice & Prentice & Prentice
Prior True True True True
Parameter Scenario Value Mean (SD) ¯PSD Value Mean (SD) ¯PSD Value Mean (SD) ¯PSD Value Mean (SD) ¯PSD
µs0 1
1 4 4.00(0.07) 0.08 4 4.00(0.08) 0.08 4 4.00(0.09) 0.08 4 4.00(0.08) 0.08
22 4.00(0.09) 0.08 4.01(0.08) 0.08 4.00(0.08) 0.08 4.00(0.08) 0.08
33 4.00(0.08) 0.08 4.00(0.08) 0.08 4.01(0.08) 0.08 4.00(0.09) 0.08
44 3.99(0.08) 0.08 4.01(0.08) 0.08 3.99(0.08) 0.08 4.00(0.08) 0.08
µs1 1 6 5.99(0.07) 0.08 6 5.99(0.09) 0.08 6 6.00(0.08) 0.08 6 6.00(0.08) 0.08
2 6.01(0.08) 0.08 5.99(0.07) 0.08 5.99(0.08) 0.08 6.00(0.08) 0.08
3 6.00(0.08) 0.08 6.00(0.08) 0.08 6.00(0.08) 0.08 5.99(0.08) 0.08
4 6.01(0.08) 0.08 5.99(0.08) 0.08 5.99(0.08) 0.08 5.99(0.09) 0.08
µt0 1 7.8 7.80(0.08) 0.08 9 9.00(0.08) 0.08 8.5 8.51(0.08) 0.08 8.4 8.40(0.08) 0.08
2 7.80(0.09) 0.08 9.00(0.08) 0.08 8.50(0.08) 0.08 8.39(0.08) 0.08
3 7.80(0.08) 0.08 9.00(0.09) 0.08 8.50(0.08) 0.08 8.40(0.08) 0.08
4 7.78(0.08) 0.08 9.00(0.08) 0.08 8.49(0.07) 0.08 8.40(0.08) 0.08
µt1 1 10 9.99(0.08) 0.08 10 9.99(0.08) 0.08 10 10.00(0.09) 0.08 10 10.00(0.08) 0.08
2 10.00(0.08) 0.08 10.00(0.08) 0.08 9.99(0.08) 0.08 10.00(0.07) 0.08
3 10.00(0.07) 0.08 10.00(0.08) 0.08 9.99(0.08) 0.08 9.99(0.08) 0.08
4 10.01(0.09) 0.08 10.00(0.08) 0.08 10.00(0.08) 0.08 10.00(0.09) 0.08
σs0 1 1 1.01(0.06) 0.09 1 1.00(0.05) 0.07 1 1.02(0.06) 0.08 1 1.01(0.06) 0.09
2 1.00(0.06) 0.06 1.00(0.06) 0.06 1.00(0.06) 0.06 1.00(0.06) 0.06
3 1.00(0.05) 0.06 1.00(0.06) 0.06 1.01(0.06) 0.06 1.00(0.06) 0.06
4 0.99(0.06) 0.06 1.01(0.06) 0.06 1.00(0.06) 0.06 0.99(0.06) 0.06
σs1 1 1 1.01(0.06) 0.09 1 1.00(0.06) 0.08 1 1.01(0.06) 0.07 1 1.01(0.06) 0.09
2 1.00(0.06) 0.06 1.01(0.05) 0.06 1.01(0.06) 0.06 1.00(0.06) 0.06
3 1.00(0.05) 0.06 1.01(0.06) 0.06 1.01(0.06) 0.06 0.99(0.06) 0.06
4 1.00(0.06) 0.06 1.01(0.05) 0.06 1.01(0.05) 0.06 0.99(0.06) 0.07
σt0 1 1 1.00(0.06) 0.09 1 1.01(0.06) 0.08 1 1.01(0.06) 0.07 1 1.01(0.06) 0.10
2 1.00(0.06) 0.06 1.00(0.05) 0.06 1.01(0.06) 0.06 1.00(0.06) 0.06
3 1.00(0.05) 0.06 1.01(0.06) 0.06 1.02(0.06) 0.06 0.99(0.05) 0.06
4 1.00(0.06) 0.06 1.01(0.06) 0.06 1.01(0.06) 0.06 0.99(0.05) 0.06
σt1 1 1 1.01(0.06) 0.09 1 1.00(0.06) 0.08 1 1.02(0.06) 0.07 1 1.01(0.06) 0.10
2 1.00(0.06) 0.06 1.00(0.06) 0.06 1.00(0.06) 0.06 1.00(0.06) 0.06
3 1.00(0.06) 0.06 1.00(0.06) 0.06 1.01(0.05) 0.06 1.00(0.06) 0.06
4 1.01(0.06) 0.06 1.00(0.06) 0.06 1.01(0.06) 0.06 0.99(0.06) 0.06
ρ00 1 0.7 0.68(0.04) 0.05 0.5 0.48(0.07) 0.06 0.2 0.19(0.07) 0.08 0.8 0.78(0.03) 0.03
2 0.68(0.04) 0.04 0.48(0.06) 0.06 0.20(0.07) 0.07 0.79(0.03) 0.03
3 0.69(0.04) 0.04 0.48(0.06) 0.06 0.20(0.07) 0.07 0.78(0.03) 0.03
4 0.68(0.04) 0.04 0.48(0.06) 0.06 0.20(0.07) 0.07 0.79(0.03) 0.03
ρ11 1 0.7 0.68(0.04) 0.05 0.5 0.48(0.07) 0.06 0.2 0.18(0.08) 0.08 0.8 0.78(0.03) 0.04
2 0.68(0.05) 0.04 0.49(0.06) 0.06 0.19(0.07) 0.07 0.79(0.03) 0.03
3 0.68(0.04) 0.04 0.49(0.07) 0.06 0.20(0.07) 0.07 0.78(0.03) 0.03
4 0.69(0.04) 0.04 0.49(0.06) 0.06 0.20(0.06) 0.07 0.78(0.03) 0.03
Unidentified Parameters
ρs 1 0.5 -0.35(0.23) 0.33 0.5 -0.22(0.22) 0.35 0.2 -0.15(0.23) 0.37 0.4 -0.35(0.24) 0.34
2 0.32(0.08) 0.19 0.39(0.07) 0.22 0.37(0.08) 0.22 0.24(0.07) 0.15
3 0.34(0.06) 0.13 0.45(0.05) 0.16 0.46(0.06) 0.21 0.22(0.04) 0.10
4 0.47(0.07) 0.18 0.43(0.06) 0.20 0.34(0.06) 0.21 0.43(0.08) 0.16
ρ01 1 0.15 -0.45(0.21) 0.29 0.45 -0.28(0.21) 0.33 0.04 -0.18(0.23) 0.35 0.32 -0.48(0.22) 0.29
2 0.32(0.08) 0.19 0.39(0.07) 0.22 0.37(0.06) 0.22 0.24(0.07) 0.15
3 0.14(0.04) 0.11 0.16(0.03) 0.10 0.06(0.02) 0.04 0.09(0.03) 0.07
4 0.40(0.08) 0.20 0.28(0.07) 0.19 0.14(0.04) 0.15 0.40(0.09) 0.18
ρ10 1 0.15 -0.37(0.21) 0.32 0.45 -0.28(0.24) 0.34 0.04 -0.16(0.23) 0.35 0.32 -0.39(0.21) 0.33
2 0.34(0.08) 0.19 0.39(0.07) 0.22 0.37(0.07) 0.22 0.24(0.07) 0.15
3 0.15(0.04) 0.11 0.16(0.02) 0.11 0.06(0.02) 0.04 0.10(0.03) 0.08
4 0.42(0.08) 0.19 0.28(0.07) 0.19 0.14(0.03) 0.14 0.42(0.08) 0.17
ρt 1 0.18 -0.47(0.19) 0.27 0.5 -0.32(0.23) 0.32 0.3 -0.18(0.22) 0.36 0.4 -0.53(0.18) 0.28
2 0.31(0.08) 0.19 0.37(0.07) 0.22 0.37(0.07) 0.22 0.24(0.06) 0.16
3 0.32(0.05) 0.13 0.44(0.05) 0.16 0.46(0.06) 0.21 0.21(0.04) 0.09
4 0.45(0.07) 0.19 0.42(0.06) 0.20 0.34(0.05) 0.21 0.42(0.08) 0.17
1: No restrictions on ρ
2: ρ ≥ 0
3: ρ ≥ 0 and ρ10, ρ01 < ρs, ρt, ρ00, ρ11
4: Beta priors
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Table 3: Simulation results: Bias, variability and coverage rate of surrogacy parame-
ters
S Valid PS, S Invalid PS, S Invalid PS S Valid PS
S Invalid Prentice S Valid Prentice & Prentice & Prentice
Prior True 95% True 95% True 95% True 95%
Parameter Scenario Value Mean (SD) ¯PSD Coverage Value Mean (SD) ¯PSD Coverage Value Mean (SD) ¯PSD Coverage Value Mean (SD) ¯PSD Coverage
β1 1 0.8 0.81(0.42) 0.51 0.99 0 0.06(0.60) 0.56 0.93 1.1 1.15(0.59) 0.59 0.96 0 0.05(0.36) 0.47 0.99
2 0.82(0.45) 0.44 0.96 0.02(0.51) 0.52 0.96 1.18(0.54) 0.54 0.96 0.03(0.37) 0.37 0.95
3 0.84(0.44) 0.43 0.94 0.04(0.56) 0.52 0.93 1.07(0.51) 0.55 0.98 -0.01(0.35) 0.07 0.96
4 0.78(0.43) 0.44 0.94 0.004(0.51) 0.52 0.95 1.10(0.54) 0.54 0.96 0.04(0.37) 0.38 0.95
β2 1 0.7 0.68(0.06) 0.07 0.96 0.5 0.49(0.08) 0.08 0.94 0.2 0.19(0.08) 0.08 0.96 0.8 0.78(0.05) 0.07 0.97
2 0.69(0.06) 0.06 0.97 0.49(0.07) 0.07 0.96 0.21(0.07) 0.08 0.97 0.79(0.05) 0.05 0.96
3 0.69(0.06) 0.06 0.96 0.49(0.08) 0.07 0.93 0.20(0.07) 0.07 0.94 0.78(0.05) 0.05 0.93
4 0.68(0.06) 0.06 0.97 0.49(0.07) 0.07 0.94 0.20(0.07) 0.07 0.95 0.79(0.05) 0.05 0.97
β3 1 0 0.004(0.08) 0.10 0.99 0 -0.008(0.12) 0.11 0.95 0 -0.0007(0.11) 0.11 0.96 0 -0.004(0.07) 0.09 0.98
2 0.001(0.08) 0.09 0.96 0.002(0.10) 0.10 0.95 -0.01(0.10) 0.10 0.96 0.001(0.07) 0.07 0.94
3 -0.002(0.08) 0.08 0.95 -0.001(0.11) 0.10 0.92 0.004(0.10) 0.11 0.97 0.007(0.07) 0.07 0.96
4 0.010(0.08) 0.08 0.96 0.006(0.10) 0.10 0.95 0.003(0.10) 0.10 0.96 -0.002(0.07) 0.07 0.96
γ0 1 0 0.54(0.23) 0.38 0.72 0.8 -0.33(0.33) 0.54 0.27 1.1 0.81(0.41) 0.66 0.97 0 -0.25(0.21) 0.33 0.96
2 1.09(0.26) 0.52 0.49 0.64(0.28) 0.70 1 2.07(0.28) 0.65 0.69 0.12(0.17) 0.37 1
3 0.54(0.15) 0.31 0.70 -0.30(0.23) 0.50 0.01 0.82(0.22) 0.45 1 -0.19(0.11) 0.20 0.92
4 1.10(0.26) 0.63 0.60 0.18(0.26) 0.67 0.96 1.30(0.20) 0.48 0.99 0.20(0.22) 0.51 1
γ1 1 1.1 0.83(0.11) 0.19 0.68 0.1 0.66(0.16) 0.26 0.27 0.2 0.34(0.20) 0.32 0.97 0.8 0.92(0.10) 0.16 0.94
2 0.55(0.12) 0.26 0.48 0.28(0.13) 0.35 1 -0.29(0.12) 0.32 0.64 0.74(0.08) 0.18 1
3 0.83(0.06) 0.15 0.63 0.65(0.10) 0.24 0 0.34(0.10) 0.22 1 0.90(0.04) 0.09 0.91
4 0.55(0.12) 0.31 0.60 0.41(0.12) 0.33 0.97 0.11(0.08) 0.23 1 0.70(0.11) 0.25 1
ρST 1 0.86 0.77 (0.06) 0.11 0.97 0.1 0.60 (0.11) 0.18 0.26 0.21 0.31 (0.16) 0.26 0.99 0.8 0.85 (0.04) 0.08 0.95
2 0.53(0.10) 0.20 0.54 0.17 (0.10) 0.29 1 -0.27 (0.10) 0.27 0.63 0.73(0.06) 0.12 1
3 0.81(0.04) 0.09 1 0.62 (0.06) 0.15 0 0.31 (0.07) 0.14 1 0.89 (0.02) 0.05 0.73
4 0.52(0.09) 0.23 0.68 0.38(0.09) 0.26 0.97 0.10(0.07) 0.20 1 0.66(0.08) 0.17 0.99
γ0 + γ1(µS1 − µS0 + 2SDS(1)−S(0)) 1 4.4 4.86 (0.39) 0.57 0.90 1.2 2.97 (0.49) 0.67 0.27 2.0 2.47 (0.52) 0.80 0.96 3.35 4.59 (0.37) 0.57 0.31
2 3.45 (0.28) 0.50 0.46 1.37 (0.26) 0.64 1 0.89 (0.25) 0.61 0.56 3.40 (0.24) 0.38 0.99
3 4.08 (0.21) 0.32 0.93 2.31 (0.20) 0.39 0 2.10 (0.18) 0.28 1 3.81 (0.18) 0.24 0.49
4 3.31 (0.26) 0.55 0.36 1.82 (0.23) 0.58 0.96 1.74 (0.19) 0.45 1 3.02 (0.27) 0.45 0.96
γ0 + γ1(µS1 − µS0 − 2SDS(1)−S(0)) 1 0 -0.47 (0.38) 0.57 0.87 0.8 -1.00 (0.47) 0.67 0.25 0.99 0.51 (0.52) 0.79 0.95 -0.15 -1.39 (0.40) 0.57 0.31
2 0.96 (0.30) 0.50 0.44 0.63 (0.27) 0.64 1 2.11 (0.26) 0.61 0.58 -0.19 (0.24) 0.38 0.99
3 0.31 (0.22) 0.32 0.91 -0.30 (0.23) 0.39 0.02 0.88 (0.18) 0.28 1 -0.62 (0.17) 0.24 0.45
4 1.14 (0.26) 0.54 0.32 0.18 (0.25) 0.58 0.96 1.29 (0.20) 0.45 0.97 0.18 (0.25) 0.45 0.96
Φ10(0) 1 0.5 0.69 (0.08) 0.13 0.72 0.79 0.40 (0.09) 0.16 0.24 0.83 0.70 (0.10) 0.16 0.95 0.5 0.39 (0.08) 0.14 0.96
2 0.84 (0.06) 0.13 0.49 0.70 (0.08) 0.20 1 0.95 (0.02) 0.07 0.69 0.55 (0.08) 0.18 1
3 0.77 (0.07) 0.15 0.70 0.38 (0.08) 0.19 0.16 0.78 (0.06) 0.15 1 0.36 (0.07) 0.14 0.92
4 0.85 (0.07) 0.16 0.60 0.56 (0.09) 0.23 0.96 0.86 (0.04) 0.10 1 0.58 (0.10) 0.23 1
1: No restrictions on ρ
2: ρ ≥ 0
3: ρ ≥ 0 and ρ10, ρ01 < ρs, ρt, ρ00, ρ11
4: Beta priors
Table 4: Simulation results: Principal Surrogacy Assessment
Model 1 2 3 4
Truth
PS satisfied Yes No No Yes
Prentice satisfied No Yes No Yes
Estimation Results
γ0 = 0 Not Rejected, Reject γ1 = 0 0.37 0.15 0.01 0.94
Reject ρST = 0 0.57 0.17 0.01 0.94
CEPU−2SD < CEP
L
+2SD 0.55 0.15 0.01 0.93
Φ10(0) = 0.5 Not Rejected 0.60 1 0.20 1
Prentice Criteria Not Rejected 0.52 0.92 0.26 0.95
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